Share familial Alzheimer's genetic panel results with a dementia patient in short, simple sessions, confirm consent for who else learns the results before you disclose anything, and bring in a genetic counselor to manage both the patient's and family's reactions. As symptoms progress, the person who was tested may understand less of what a result means, so the conversation has to adapt rather than happen once and end. A familial Alzheimer's genetic panel checks three genes — APP, PSEN1, and PSEN2 — tied to early-onset, inherited forms of the disease. PSEN1 mutations cause up to roughly 70% of early-onset familial cases, APP about 15%, and PSEN2 under 5%, so a positive result on one gene carries a different weight than on another, according to Pathology Tests Explained.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the Results Actually Mean Before You Discuss Them
- Deciding Who Learns the Result, and When
- Why Families Struggle to Share Results With Each Other
- Models Worth Knowing, and Why Most Relatives Decline to Test At All
- Planning for the Emotional Aftermath, Not Just the Conversation
- Frequently Asked Questions
What the Results Actually Mean Before You Discuss Them
A positive result on PSEN1, APP, or PSEN2 confirms a disease-causing mutation runs in the family, but a negative result does not necessarily rule out an inherited cause. Commercial lab data show these three genes are identified in only 60–80% of early-onset Alzheimer's cases, so 20–40% of people tested get an uninformative result — negative, but not reassuring — according to ARUP Laboratories' test fact sheet.
That distinction matters when you talk to a patient or family member about "the test came back negative." A negative result can still leave open the possibility that an undetected mutation, or a gene not covered by the panel, is driving the disease. Say plainly what was tested and what wasn't, rather than letting a negative result sound like closure it may not provide.
Deciding Who Learns the Result, and When
Before any result is disclosed, revisit with the patient — while they can still participate in that conversation — who else should be told and how. The National Society of Genetic Counselors' practice guideline calls for this to be addressed explicitly after disclosure, along with a scheduled follow-up check-in, not left to work itself out informally, according to the NSGC guideline. This becomes harder once the disease progresses.
The same guideline directs counselors to assess the psychological state of both the patient and any accompanying family member, and to watch for conflicts of interest when a relative is the one pushing for testing on a person who is already symptomatic. A family member requesting results for someone who can no longer weigh in on disclosure decisions is exactly the scenario the guideline flags. In practice:.
- Confirm, early and in writing if possible, exactly who the patient wants informed.
- Revisit that list before disclosure if cognition has changed since testing was ordered.
- Treat a relative's insistence on testing or disclosure as a signal to check for conflicting motives, not just logistics.
Why Families Struggle to Share Results With Each Other
A 2023 qualitative study of family members of people with younger-onset dementia found that communicating genetic test results within families is complicated by family dynamics, incomplete understanding of genetics, reluctance to deliver distressing news, and the cognitive and behavioral effects of the disease itself on the person tested, according to the study published via PMC. These aren't separate problems — they compound. A family member may want to protect a sibling from distressing news, but not understand the inheritance pattern well enough to explain it accurately, while the patient's own behavioral changes make a calm conversation harder to schedule.
A related study of memory-clinic settings found that genetic counselors should proactively address anticipated family tension before testing occurs, and extend psychological support to relatives, not just the person tested. Conflict often doesn't surface until a progressing patient can no longer fully participate in decisions about who is told, according to the Dutch qualitative study on genetic testing for familial dementia. That argues for raising the disclosure plan well before symptoms worsen, not waiting until a crisis forces the question.
Models Worth Knowing, and Why Most Relatives Decline to Test At All
Large research cohorts studying inherited Alzheimer's have built disclosure safeguards worth understanding, even for families outside a study. The Dominantly Inherited Alzheimer Network (DIAN) offers enrolled participants free genetic counseling and testing for familial mutations as a courtesy outside the research protocol itself, and keeps results from reaching site coordinators and investigators, so participation never requires knowing one's own mutation status, according to DIAN at Washington University. Most people in that position choose not to find out.
An Alzforum report on DIAN noted that at one point only about 20 of roughly 290 enrolled participants had chosen to learn their genetic status, even with free testing offered — though those figures are several years old and participation may have shifted since, according to Alzforum's reporting. A newer protocol, described in a 2025 paper on the NIA Alzheimer's Family-Based Study, restricts eligibility further: of six genes tied to autosomal dominant dementia (APP, PSEN1, PSEN2, MAPT, GRN, C9orf72), only the family member with the earliest disease onset in a multiplex family is eligible to receive results, through a four-step process of consent, pre-test counseling, testing, and disclosure with post-test counseling, according to the NIA study protocol. The pattern across both programs is the same: disclosure is treated as a deliberate, staged decision, not a default outcome of testing.
Planning for the Emotional Aftermath, Not Just the Conversation
A negative result is not automatically a relief. A small outcomes study of 22 at-risk individuals found that, one year after receiving familial Alzheimer's genetic results, people who tested negative reported testing-related distress at a level similar to those who tested positive, according to the psychological-outcomes study. Build in follow-up support regardless of which way the result goes.
- Schedule a follow-up check-in after disclosure, as the NSGC guideline recommends, rather than treating the disclosure meeting as the end of the process.
- Offer support to relatives present for the conversation, not only the person tested.
- Watch for distress in a family member who tested negative; don't assume the news landed as good.
- Revisit the disclosure plan if the patient's capacity to participate in decisions changes after the initial conversation.
Frequently Asked Questions
Does a negative result on the panel rule out inherited Alzheimer's in the family?
Not necessarily. Commercial lab data show APP, PSEN1, and PSEN2 explain only 60–80% of early-onset cases, so 20–40% of negative results don't rule out an inherited cause, according to ARUP Laboratories.
Who should be told the results first?
The patient's own wishes, confirmed before disclosure and revisited if their cognition changes, per the NSGC guideline's recommendation to explicitly address this after disclosure, according to the NSGC guideline.
If someone tests negative, can the conversation stop there?
No — a one-year outcomes study found negative-result distress can match positive-result distress, so follow-up support matters either way, according to the psychological-outcomes study.
You Might Also Like
- Familial Alzheimer’s Genetic Panel When Dementia Symptoms Progress: Cost, Coverage, and Referral Questions
- Familial Alzheimer’s Genetic Panel When Dementia Symptoms Progress: Accuracy, Preparation, and Next Steps
- Can Familial Alzheimer’s Genetic Panel Change Dementia Care Decisions When Dementia Symptoms Progress?
